Deucravacitinib Safety Data and Treatment Selection Considerations

Opinion
Video

Bruce Strober, MD, PhD, and Linda Stein Gold, MD, provide clinical insights on long-term safety data for deucravacitinib and selecting the right treatment for the right patient.

0:05 Long-term Safety Data of Deucravacitinib

6:55 Selecting the Right Treatment for the Right Patient

Related Videos
Linda Stein Gold, MD, and Bruce Strober, MD, PhD
Linda Stein Gold, MD, and Bruce Strober, MD, PhD
Hong-Uyen Hua, MD; Sruthi Arepalli, MD; and Peter Kaiser, MD
Kelly Nichols, OD; Laura Periman, MD; and Mile Brujic, OD
Mona SHahriari, MD | Credit: Central Connecticut Dermatology
Mona Shahriari, MD | Credit Central Connecticut Dermatology
How Psoriatic Arthritis Presentation, Treatment Has Evolved
Related Content
Interclass Versus Intraclass Switching: IL-23, IL-17A Inhibitors for Psoriasis

Interclass Versus Intraclass Switching: IL-23, IL-17A Inhibitors for Psoriasis

Tim Smith
June 27th 2024
Article
MEDcast logo

Beyond the Surface: Monitoring your Patients with Moderate to Severe Plaque Psoriasis

Linda Stein Gold, MD;Bruce Strober, MD, PhD, FAAD
June 26th 2024
Podcast
Quality of Life Perceptions Correlate with PASI Score Reductions Among Psoriasis Patients

Quality of Life Perceptions Correlate with PASI Score Reductions Among Psoriasis Patients

Tim Smith
June 25th 2024
Article
A Patient-Centric Medcast on the Journey Through Moderate Plaque Psoriasis

A Patient-Centric Medcast on the Journey Through Moderate Plaque Psoriasis

Lauren Miller, MPAS, PA-C;Jayme M Heim, MSN, FNP-BC;Terry Faleye, MPAS, PA-C
February 28th 2024
Podcast
Apremilast Effective, Safe Among Psoriasis Patients with Special Area Involvement

Apremilast Effective, Safe Among Psoriasis Patients with Special Area Involvement

Tim Smith
June 24th 2024
Article
Hand Eczema Significantly Reduces Quality of Life

Hand Eczema Significantly Reduces Quality of Life

Chelsie Derman
June 24th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.